Tuesday 18 March 2025

Pharma & Biotech Start-up & Scale-up News

Featured

Latigo Biotherapeutics
A clinical-stage biotech company developing best-in-class non-opioid pain medicines.
Pharmaceutical
Lexicon pivots back to pipeline after FDA rejection
25 November 2024
Pharmaceutical
The week in pharma: action, reaction and insight – week to November 1
3 November 2024

Latest Ones To Watch News

Biotechnology
Latigo’s $150 million Series B to advance non-opioid pain drugs
17 March 2025
Biotechnology
Taiho to buy Araris for up to $1.14 billion
17 March 2025
Biotechnology
iOnctura strengthens leadership team
17 March 2025
More ones to watch news >
Reset all filters
Refine Search
Pliant Therapeutics
Pliant Therapeutics
Nuvation Bio
Nuvation Bio
Enanta Pharmaceuticals
Basilea
Exsilio Therapeutics
Aphaia Pharma
Avextra
Aurion Biotech
āshibio
UTILITY Therapeutics
Enlaza Therapeutics
Jacobio Pharma
SFA Therapeutics
Reunion Neuroscience
Atopia Therapeutics
Prologue Medicines
Lykos Therapeutics
Attovia Therapeutics
Ajax Therapeutics
Cartesian Therapeutics


Today's issue

Latigo’s $150 million Series B to advance non-opioid pain drugs
Biotechnology
Latigo’s $150 million Series B to advance non-opioid pain drugs
17 March 2025
Biotechnology
Taiho to buy Araris for up to $1.14 billion
17 March 2025
Biotechnology
iOnctura strengthens leadership team
17 March 2025
Pharmaceutical
The Make America Healthy Again Commission: Restructuring America’s healthcare
17 March 2025
Pharmaceutical
Partners aim to develop new class of obesity therapeutics
17 March 2025
Pharmaceutical
Russia experiencing antidepressants sales boom this year
17 March 2025
Pharmaceutical
Eneboparatide met primary Phase III endpoint, says AstraZeneca
17 March 2025

Company Spotlight

A clinical-stage biotech company developing best-in-class non-opioid pain medicines.




Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze